Cardiac workup after cerebral ischemia: Consensus paper of the Working Group on Heart and Brain of the German Cardiac Society and German Stroke Society;Kardiologische diagnostik nach zerebraler ischämie: Konsensuspapier der Arbeitsgemeinschaft Herz und Hirn der Deutschen Gesellschaft für Kardiologie - Herz- und Kreislaufforschung e.V. (DGK) und der Deutschen Schlaganfallgesellschaft e.V. (DSG)

Nervenarzt

Volumn 81, Issue 4, 2010, Pages 444-462

  Laufs, U ^a   Hoppe, U C ^b   Rosenkranz, S ^b   Kirchhof, P ^c   Bohm M ^a   Diener, H C ^d   Endres, M ^e   Grond, M ^f   Hacke, W ^g   Meinertz, T ^h   Ringelstein, E B ⁱ   Rother J ^j   Dichgans, M ^k  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c Medizinische Klinik und Poliklinik C   (Germany)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f Klinik für Neurologie   (Germany)

^g UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^h UNIVERSITY HEART CENTER HAMBURG   (Germany)

ⁱ Klinik und Poliklinik für Neurolgie   (Germany)

^j KLINIKUM MINDEN   (Germany)

^k LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CHOLESTEROL; CLOPIDOGREL; GLUCOSE; HOMOCYSTEINE; NATRIURETIC PEPTIDE RECEPTOR B; TROPONIN; WARFARIN;

ANGIOCARDIOGRAPHY; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM EXAMINATION; CHOLESTEROL BLOOD LEVEL; CONSENSUS; DIABETES MELLITUS; DIAGNOSTIC TEST; ELECTROCARDIOGRAPHY; ENDOCARDITIS; GLUCOSE BLOOD LEVEL; HEART WORK; HUMAN; INFLAMMATION; MEDICAL SOCIETY; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATENT FORAMEN OVALE; PATIENT MONITORING; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TELEMEDICINE; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

EID: 77953646776     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-009-2901-3     Document Type: Review

References (151)

1. Diener HC, Putzki N et al (2008) Leitlinien der DGN 2008. In: Kommission " Leitlinien der Deutschen Gesellschaft für Neurologie" (Hrsg) Leitlinien für Diagnostik und Therapie in der Neurologie
2. The Europeen Stroke Organization (ESO) Executive Committe and the ESO Writing Committee (2008) Guidelines for managment of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 25:457-507
3. Capes SE, Hunt D, Malmberg K et al (2001) Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke 32:2426-2432
4. Alvarez-Sabin J, Molina CA, Montaner J et al (2003) Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator-treated patients. Stroke 34:1235-1241
5. McCormick MT, Muir KW, Gray CS et al (2008) Management of hyperglycemia in acute stroke: how, when, and for whom? Stroke 39:2177-2185
6. Fuentes B, Castillo J, San JB et al (2009) The prognostic value of capillary glucose levels in acute stroke: the GLycemia in Acute Stroke (GLIAS) Study. Stroke 40:562-568
7. Ringleb PA et al (2009) Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008. The European Stroke Organization (ESO) Executive Committee and the ESO Writing Committee. http://www.eso-stroke.org/ pdf/ESO%20Guidelines-update-Jan-2009.pdf
8. Gray CS, Hildreth AJ, Sandercock PA et al (2007) Glucose-potassium- insulin infusions in the management of post-stroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK). Lancet Neurol 6:397-406
9. Yong M, Kaste M (2008) Dynamic of hyperglycemia as a predictor of stroke outcome in the ECASS-II trial. Stroke 39:2749-2755
10. Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. Eur Heart J [Suppl 9]:C3-C74
11. Kerner W, Brückel J (2007) Definition, Klassifikation und Diagnostik. Diabetologie [Suppl 2]:147-149
12. Prospective Studies Collaboration, Lewington S, Whitlock G, Clarke R et al (2007) Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370:1829-1839
13. Kurth T, Everett BM, Buring JE et al (2007) Lipid levels and the risk of ischemic stroke in women. Neurology 68:556-562
14. Sanossian N, Tarlov NE (2008) HDL-C and LDL-C: their role in stroke pathogenesis and implications for treatment. Curr Treat Options Cardiovasc Med 10:195-206
15. Bansal S, Buring JE, Rifai N et al (2007) Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 298:309-316
16. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS et al (2008) Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 300:2142-2152
17. Bang OY, Saver JL, Liebeskind DS et al (2008) Association of serum lipid indices with large artery atherosclerotic stroke. Neurology 70:841-847
18. Kamstrup PR, Tybjærg-Hansen A, Steffensen R et al (2009) Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 301:2331-2339
19. Amarenco P, Labreuche J (2009) Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 8:453-463
20. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial. Lancet 360:7-22
21. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators (2006) High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355:549-559
22. Adams HP, Zoppo G del, Alberts MJ et al (2007) Atherosclerotic peripheral vascular disease and quality of care outcomes in research interdisciplinary working groups. Stroke 38:1655-1711
23. Sacco RL, Adams R, Albers G et al (2006) Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation 113:409-449
24. Pezzini A, Del ZE, Magoni M et al (2003) Inherited thrombophilic disorders in young adults with ischemic stroke and patent foramen ovale. Stroke 34:28-33
25. Botto N, Spadoni I, Giusti S et al (2007) Prothrombotic mutations as risk factors for cryptogenic ischemic cerebrovascular events in young subjects with patent foramen ovale. Stroke 38:2070-2073
26. Buller HR, Agnelli G, Hull RD et al (2004) Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 [Suppl 3]:401-428
27. Lim W, Crowther MA, Eikelboom JW (2006) Management of antiphospholipid antibody syndrome: a systematic review. JAMA 295:1050-1057
28. Homocysteine Studies Collaboration (2002) Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288:2015-2022
29. Toole JF, Malinow MR, Chambless LE et al (2004) Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 291:565-575
30. Bonaa KH, Njolstad I, Ueland PM et al (2006) Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354:1578-1588
31. Lonn E, Yusuf S, Arnold MJ et al (2006) Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354:1567-1577
32. Liman T, Endres M (2008) Elevated troponin and ECG alterations in acute ischemic stroke and subarachnoid hemorrhage. Nervenarzt 79:1386-1398
33. Jensen JK, Kristensen SR, Bak S et al (2007) Frequency and significance of troponin T elevation in acute ischemic stroke. Am J Cardiol 99108-99112
34. James P, Ellis CJ, Whitlock RM et al (2000) Relation between troponin T concentration and mortality in patients presenting with an acute stroke: observational study. BMJ 320:1502-1504
35. Di AE, Fiorelli M, Toni D et al (2005) Prognostic significance of admission levels of troponin I in patients with acute ischaemic stroke. J Neurol Neurosurg Psychiatry 76:76-81
36. Rubattu S, Sciarretta S, Valenti V et al (2008) Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. Am J Hypertens 21:733-741
37. Kistorp C, Raymond I, Pedersen F et al (2005) N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 293:1609-1616
38. Di NM, Schwaninger M, Cappelli R et al (2005) Evaluation of C-reactive protein measurecument for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke 36:1316-1329
39. Elkind MS (2009) Inflammatory markers and stroke. Curr Cardiol Rep 11:12-20
40. Ridker PM, Danielson E, Fonseca FA et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195-2207
41. Ross R (1999) Atherosclerosis-an inflammatory disease. N Engl J Med 340:115-126
42. Ridker PM, Buring JE, Rifai N et al (2007) Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 297:611-619
43. Ridker PM, Cannon CP, Morrow D et al (2005) C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352:20-28
44. Grau AJ, Weimar C, Buggle F et al (2001) Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke 32:559-566
45. Dimant J, Grob D (1977) Electrocardiographic changes and myocardial damage in patients with acute cerebrovascular accidents. Stroke 8:448-455
46. Oppenheimer SA (1994) Neurogenic cardiac effects of cerebrovascular disease. Curr Opin Neurol 7:20-24
47. Oppenheimer SM, Hachinski VC (1992) The cardiac consequences of stroke. Neurol Clin 10:167-176
48. Mikolich JR, Jacobs WC, Fletcher GF (1981) Cardiac arrhythmias in patients with acute cerebrovascular accidents. JAMA 246:1314-1317
49. Norris JF, Froggatt GM, Hachinski VC (1978) Cardiac arrhythmias in acute stroke. Stroke 9:392-396
50. Hohnloser SH, Pajitnev D, Pogue J et al (2007) Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. J Am Coll Cardiol 50:2156-2161
51. Fuster V, Ryden LE, Cannom DS et al (2006) ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J 27:1979-2030 (Pubitemid 44313588)
52. Hart RG, Pearce LA, Aguilar MI (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146:857-867
53. Kirchhof P, Auricchio A, Bax J et al (2007) Outcome parameters for trials in atrial fibrillation: executive summary: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). Eur Heart J 28:2803-2817 (Pubitemid 350135529)
54. Fetsch T, Bauer P, Engberding D et al (2004) Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J 25:1385-1394
55. Page RL, Wilkinson WE, Clair WK et al (1994) Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 89:224-227
56. Brignole M, Vardas P, Hoffman E et al (2009) Indications for the use of diagnostic implantable and external ECG loop recorders. Europace 11:671-687
57. Barthelemy JC, Feasson-Gerard S, Garnier P et al (2003) Automatic cardiac event recorders reveal paroxysmal atrial fibrillation after unexplained strokes or transient ischemic attacks. Ann Noninvasive Electrocardiol 8:194-199
58. Hornig CR, Haberbosch W, Lammers C et al (1996) Specific cardiological evaluation after focal cerebral ischemia. Acta Neurol Scand 93:297-302
59. Jabaudon D, Sztajzel J, Sievert K et al (2004) Usefulness of ambulatory 7-day ECG monitoring for the detection of atrial fibrillation and flutter after acute stroke and transient ischemic attack. Stroke 35:1647-1651
60. Liao J, Khalid Z, Scallan C et al (2007) Noninvasive cardiac monitoring for detecting paroxysmal atrial fibrillation or flutter after acute ischemic stroke: a systematic review. Stroke 38:2935-2944
61. Rem JA, Hachinski VC, Boughner DR et al (1985) Value of cardiac monitoring and echocardiography in TIA and stroke patients. Stroke 16:950-956
62. Schaer BA, Zellweger MJ, Cron TA et al (2004) Value of routine holter monitoring for the detection of paroxysmal atrial fibrillation in patients with cerebral ischemic events. Stroke 35:68-70
63. Schuchert A, Behrens G, Meinertz T (1999) Impact of long-term ECG recording on the detection of paroxysmal atrial fibrillation in patients after an acute ischemic stroke. Pacing Clin Electrophysiol 22:1082-1084
64. Shafqat S, Kelly PJ, Furie KL (2004) Holter monitoring in the diagnosis of stroke mechanism. Intern Med J 34:305-309
65. Tayal AH, Tian M, Kelly KM et al (2008) Atrial fibrillation detected by mobile cardiac outpatient telemetry in cryptogenic TIA or stroke. Neurology 71:1696-1701
66. Tagawa M, Takeuchi S, Chinushi M et al (2007) Evaluating patients with acute ischemic stroke with special reference to newly developed atrial fibrillation in cerebral embolism. Pacing Clin Electrophysiol 30:1121-1128
67. Mant J, Hobbs FD, Fletcher K et al (2007) Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA) a randomised controlled trial. Lancet 370:493-503 (Pubitemid 47212371)
68. Knecht S, Oelschlager C, Duning T et al (2008) Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. Eur Heart J 29:2125-2132
69. Miller VT, Pearce LA, Feinberg WM et al (1996) Differential effect of aspirin versus warfarin on clinical stroke types in patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. Neurology 46:238-240
70. Marini C, De Santis F, Sacco S et al (2005) Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 36:1115-1119
71. Hoppe UC, Casares JM, Eiskjaer H et al (2006) Effect of cardiac resynchronization on the incidence of atrial fibrillation in patients with severe heart failure. Circulation 114:18-25
72. Israel CW, Gronefeld G, Ehrlich JR et al (2004) Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. J Am Coll Cardiol 43:47-52
73. Capucci A, Santini M, Padeletti L et al (2005) Monitored atrial fibrillation duration predicts arterial embolic events in patients suffering from bradycardia and atrial fibrillation implanted with antitachycardia pacemakers. J Am Coll Cardiol 46:1913-1920
74. Glotzer TV (2008) The TRENDS Study: Is there a critical value of daily atrial tachyarrhytmia burden from device diagnostics that raises stroke risk? ACC (Abstr)
75. Glotzer TV, Hellkamp AS, Zimmerman J et al (2003) Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the Mode Selection Trial (MOST) Circulation 107:1614-1619
76. Petty GW, Brown RD Jr, Whisnant JP et al (1999) Ischemic stroke subtypes: a population-based study of incidence and risk factors. Stroke 30:2513-2516
77. Amarenco P, Röther J, Michel P et al (2006) Aortic arch atheroma and the risk of stroke. Curr Atheroscler Rep 8:343-346
78. Agmon Y, Khandheria BK, Gentile F et al (2002) Clinical and echocardiographic characteristics of patients with left atrial thrombus and sinus rhythm: experience in 20.643 consecutive transesophageal echocardiographic examinations. Circulation 105:27-31
79. Busse O, Darius H (2002) Indikationen zur Echokardiographie beim ischämischen zerebralen Insult. Nervenarzt 73:792-795 (Pubitemid 36062343)
80. Flemming KD, Brown RD Jr, Petty GW et al (2004) Evaluation and management of transient ischemic attack and minor cerebral infarction. Mayo Clin Proc 79:1071-1086
81. Handke M, Harloff A, Olschewski M et al (2007) Patent foramen ovale and cryptogenic stroke in older patients. N Engl J Med 357:2262-2268
82. Overell JR, Bone I, Less KR (2000) Interatrial septal abnormalities and stroke. A meta-analysis of case-control studies. Neurology 55:1172-1179
83. Meissner I, Whisnant JP, Khandheria BK et al (1999) Prevalence of potential risk factors for stroke assessed by transesophageal echocardiography and carotid ultrasonography: the SPARC study. Mayo Clin Proc 74:862-869
84. Mas JL, Arquizan C, Lamy C et al (2001) Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 345:1740-1746
85. Giardini A, Donti A, Formigari R et al (2004) Comparison of results of percutaneous closure of patent foramen ovale for paradoxical embolism in patients with versus without thrombophilia. Am J Cardiol 94:1012-1016
86. Goel SS, Tuzcu EM, Shishehbor MH et al (2009) Morphology of the patent foramen ovale in asymptomatic versus symptomatic (stroke or transient ischemic attack) patients. Am J Cardiol 103:124-129
87. Homma S, Sacco RL, Di Tullio MR et al (2002) Effect of medical treatment in stroke patients with patent foramen ovale. Circulation 105:2625-2631
88. Messe S, Silverman I, Kizer J et al (2004) Practice parameter: recurrent stroke with patent foramen ovale and atrial septal aneurysm: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 62:1042-1050 (Pubitemid 38456495)
89. Slottow TL, Steinberg DH, Waksman R (2007) Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel meeting on patent foramen ovale closure devices. Circulation 116:677-682 (Pubitemid 47356353)
90. Hung J, Landzberg MJ, Jenkins KJ et al (2000) Closure of patent foramen ovale for paradoxical emboli: intermediate-term risk of recurrent neurological events following transcatheter device placement. J Am Coll Cardiol 35:1311-1316
91. Khairy P, O'Donnell CP, Landzberg MJ (2003) Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli: a systematic review. Ann Intern Med 139:753-760
92. Braun MU, Fassbender D, Schoen SP et al (2002) Transcatheter closure of patent foramen ovale in patients with cerebral ischemia. J Am Coll Cardiol 39:2019-2025
93. Windecker S, Wahl A, Chatterjee T et al (2000) Percutaneous closure of patent foramen ovale in patients with paradoxical embolism: long-term risk of recurrent thromboembolic events. Circulation 101:893-898
94. Cifarelli A, Musto C, Parma A et al (2009) Long-term outcome of transcatheter patent foramen ovale closure in patients with paradoxical embolism. Int J Cardiol (Epub ahead of print)
95. Rigatelli G, Aggio S, Cardaioli P et al (2009) Left atrial dysfunction in patients with patent foramen ovale and atrial septal aneurysm: an alternative concurrent mechanism for arterial embolism? JACC Cardiovasc Interv 2:655-662
96. Berthet K, Lavergne T, Cohen A et al (2000) Significant association of atrial vulnerability with atrial septal abnormalities in young patients with ischemic stroke of unknown cause. Stroke 31(2):398-403
97. Wöhrle J, Kochs M, Spiess et al (2009) Impact of percutaneous device implantation for closure of patent foramen ovale on valve insufficiencies. Circulation 119:3002-3008
98. Chiarella F, Santoro E, Domenicucci S et al (1998) Predischarge two-dimensional echocardiographic evaluation of left ventricular thrombosis after acute myocardial infarction in the GISSI-3 study. Am J Cardiol 81:822-827
99. Anzola G, Morandi E, Casilli F et al (2004) Does transcatheter closure of patent foramen ovale really " shut the door?" - A prospective study with transcranial doppler. Stroke 35:2140-2144
100. Serena J, Marti-Fàbregas J, Santamarina E et al (2008) Recurrent stroke and massive right-to-left shunt: results from the prospective Spanish multicenter (CODICIA) study. Stroke 39:3131-3139
101. Torti SR, Billinger M, Schwerzmann M et al (2004) Risk of decompression illness among 230 divers in relation to the presence and size of patent foramen ovale. Eur Heart J 25:2173-2174
102. Tunick PA, Nayar AC, Goodkin GM et al (2002) NYU Atheroma Group. Effect of treatment on the incidence of stroke and other emboli in 519 patients with severe thoracic aortic plaque. Am J Cardiol 90:1320-1325
103. Cheitlin MD, Armstrong WF, Aurigemma GP et al (2003) ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J Am Coll Cardiol 42:954-970
104. Witt BJ, Gami AS, Ballman KV et al (2007) The incidence of ischemic stroke in chronic heart failure: a meta-analysis. J Card Fail 13:489-496
105. Pullicino PM, Halperin JL, Thompson JLP (2000) Stroke in patients with heart failure and reduced left ventricular ejection fraction. Neurology 54:288-294
106. Massie BM, Collins JF, Ammon SE et al (2009) WATCH Trial Investigators. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation 119:1616-1624
107. Krinsky G, Maya M, Rofsky N et al (1998) Gadolinium-enhanced 3D MRA of the aortic arch vessels in the detection of atherosclerotic cerebrovascular occlusive disease. J Comput Assist Tomogr 22:167-178
108. Ferrari E, Vidal R, Chevallier T et al (1999) Atherosclerosis of the thoracic aorta and aortic debris as a marker of poor prognosis: Benefit of oral anticoagulants. J Am Coll Cardiol 33:1317-1322
109. Ringelstein EB, Arnold M, Dittrich R et al (2008) Dissektionen hirnversorgender supraaortaler Arterien, in: Kommission " Leitlinien der Deutschen Gesellschaft für Neurologie" (Hrsg) Leitlinien für Diagnostik und Therapie in der Neurologie 288-297
110. Amarenco P, Cohen A, Tzourio C et al (1994) Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med 331:1474-1479
111. Harloff A, Strecker C, Dudler P et al (2009) Retrograde embolism from the descending aorta: visualization by multidirectional 3D velocity mapping in cryptogenic stroke. Stroke 40:1505-1508
112. Mohr JP, Thompson JL, Lazar RM et al (2001) Warfarin-Aspirin Recurrent Stroke Study Group (WARSS). A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 345:1444-1451
113. Tunick PA, Nayar AC, Goodkin GM et al (2002) Effect of treatment on the incidence of stroke and other emboli in 519 patients with severe thoracic aortic plaque. Am J Cardiol 90:1320
114. Cannegieter S, Rosendaal F, Wintzen A et al (1995) Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 333:11-17
115. Salem DN, Levine HJ, Pauker SG et al (1998) Antithrombotic therapy in valvular heart disease. Chest 114 [Suppl]:590-601
116. Bonow RO, Carabello BA, Chatterjee K et al (2008) Focused Update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. a report of the american college of cardiology/american heart association task force on practice guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease). Circulation 118:523-661
117. Gilon D, Bounanno FS, Joffe MM et al (1999) Lack of evidence of an association between mitral-valve prolapse and stroke in young patients. N Engl J Med 341:8-13
118. Baddour LM, Wilson WR, Bayer AS et al (2005) Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 111:394-434
119. Cartoni D, De Castro S, Valente G et al (2004) Identification of professional scuba divers with patent foramen ovale at risk for decompression illness. Am J Cardiol 94:270-273
120. Weimar C, Holle DN, Benemann J (2009) German Stroke Study Collaboration. Current management and risk of recurrent stroke in cerebrovascular patients with right-to-left cardiac shunt. Cerebrovasc Dis 28:349-356
121. Galiè N, Hoeper MM, Humbert M et al (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J [Epub ahead of print] PMID: 19713419
122. Kapral MK, Silver FL (1999) Preventive health care, 1999 update: 2. Echocardiography for the detection of a cardiac source of embolus in patients with stroke. Canadian Task Force on Preventive Health Care. CMAJ 161:989-996
123. Peterson GE, Brickner ME, Reimold SC (2003) Transesophageal echocardiography: Clinical indications and applications. Circulation 107:2398-2402
124. Lerakis S, Nicholson WJ (2005) Part I. Use of echocardiography in the evaluation of patients with suspected cardioembolic stroke. Am J Med Sci 329:310-316 (Pubitemid 40847699)
125. Zabalgoitia M, Halperin JL, Pearce LA et al (1998) Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol 31:1622-1626
126. Hankey GJ, Jamrozik K, Broadhurst RJ et al (2000) Five-year survival after first-ever stroke and related prognostic factors in the Perth Community Stroke Study. Stroke 31:2080-2086
127. O'Rourke RA, Brundage BH, Froelicher VF et al (2000) American College of Cardiology/American Heart Association Expert Consensus Document on Electron-Beam Computed Tomography for the Diagnosis and Prognosis of Coronary Artery Disease. Circulation 102:126-140
128. Michaelides AP, Psomadaki ZD, Dilaveris PE et al (1999) Improved detection of coronary artery disease by exercise electrocardiography with the use of right precordial leads. N Engl J Med 340:340-345
129. Baer FM (2007) Stress-ECG is the first step to assess myocardial ischemia: when are additional diagnostic tests needed? Dtsch Med Wochenschr 132:2026-2030
130. Evans A, Perez I, Yu G et al (2001) Should stroke subtype influence anticoagulation decisions to prevent recurrence in stroke patients with atrial fibrillation? Stroke 32:2828-2832
131. Sacco RL, Adams R, Albers G et al (2006) Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 37:577-617 (Pubitemid 43732031)
132. Bethesda M (1993) National cholesterol education program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). Nat Heart Lung Blood Inst, pp 93-3095
133. Law M, Wald N, Rudnicka A (2003) Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326:1423
134. Cholesterol Treatment Trialists (CTT) Collaborators (2008) Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis Lancet 371:117-125
135. Patten, M, Maas R, Bauer P et al (2004) Suppression of paroxysmal atrial tachyarrhythmias-results of the SOPAT trial. Eur Heart J 25:1395-1404
136. Botto G, Padeletti L, Santini M et al (2009) Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. J Cardiovasc Electrophysiol 20:241-248
137. Barkan D, Abu Fanne R, Elazari-Scheiman A et al (2007) Navel piercing as a cause for Streptococcus viridans endocarditis: case report, review of the literature and implications for antibiotic prophylaxis. Cardiology 108:159-160
138. Bogousslavsky J, Regli F (1987) Ischemic stroke in adults younger than 30 years of age: cause and prognosis. Arch Neurol 44:4779-4782
139. De Bruijn SF, Agema WR, Lammers GJ et al (2006) Transesophageal echocardiography is superior to transthoracic echocardiography in management of patients of any age with transient ischemic attack or stroke. Stroke 37:2531-2534
140. Di Tulio MR, Homma S (2002) Mechanisms of cardioembolic stroke. Curr Cardiol Rep 4:141-148
141. Hardman SMC, Cowie MR (1999) Anticoagulation in heart disease. Br Med J 318:238-244
142. Meyer R (2001) Piercing: Gefährlicher Körperschmuck. Dtsch Ärztebl 98:A819-A820
143. Stroke Prevention in Atrial Fibrillation Study Group (1992) Predictors of thromboembolism in atrial fibrillation. Echocardiographic features of patients at risk. Ann Intern Med 116:6-12
144. Nationale Versorgungsleitlinie (NVL) Chronische KHK (2006) Träger: Bundesärztekammer, Kassenärztliche Bundesvereinigung, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. Autoren: Donner-Banzhoff N, Held K, Laufs U et al (Hrsg: ÄZQ) http://www.versorgungsleitlinien.de/themen/khk/pdf/nvl-khk-lang.pdf
145. Bhatt DL, Steg PG, Ohman EM et al (2006) REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 295(2):180-189
146. Smith SC Jr, Allen J, Blair SN et al (2006) AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113:2363-2372 (Pubitemid 43947981)
147. Gohlke H, Albus C, Bönner G et al (2007) Leitlinie Risikoadjustierte Prävention von Herz- und Kreislauferkrankungen. Deutsche Gesellschaft Für Kardiologie - Herz- und Kreislaufforschung e.V
148. Röther J, Alberts MJ, Touzé E et al (2008) Steg on behalf of the REACH Registry Investigators Risk Factor Profile and Management of Cerebrovascular Patients in the REACH Registry. Cerebrovasc Dis 25:366-374
149. Graham I, Atar D, Borch-Johnsen K et al (2007) European guidelines on cardiovascular disease prevention in clinical practice. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil 14 [Suppl 2]:1-113
150. Sivenius J, Cunha L, Diener HC et al (1999) Antiplatelet treatment does not reduce the severity of subsequent stroke. European Stroke Prevention Study 2 Working Group. Neurology 53:825-829
151. Yilmaz A, Sechtem U (2008) Cardiac imaging in suspected coronary artery disease. Dtsch Med Wochenschr 133:644-649